EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
![](https://researchstudies.cuanschutz.edu/Content/images/study-category-images/cancer.jpg)
Details
Age
Adult
Locations
Memorial Hospital Central
Memorial Hospital North
Principal Investigator
![Photograph of Uchenna Njiaju](https://researchstudies.cuanschutz.edu/Content/images/investigators/no-photo.jpg)
Uchenna Njiaju
Study ID
Protocol Number: 22-2399
More information available at ClinicalTrials.gov: NCT05514054
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers